Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities

The Rapha Capital Mission is to use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples’ lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities.

Rapha Capital Management is focused on identifying and growing revolutionary ideas in medicine, healthcare and technology before others can see their value.

Rapha Capital Management, LLC, founded in mid-2018, has grown to include 13 managed entities, Rapha Capital Investment I – XIII.

Poseida Therapeutics Logo

Poseida Therapeutics, Inc.

NexImmune Icon

NexImmune, Inc.

Rapha Capital Latest News

NEW POST

July 25, 2022 in DELiver Therapeutics, K2 Biolabs, Portfolio, Rapha Capital Management

Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma’s Nano-in™ and No-Pass Mimic™ Nanoparticle Technologies in Anti-Aging and Other Products Initially for Skin

Ponce Therapeutic's ("Ponce") lead product, ReBeaut™, is a microneedle patch containing nanoparticles carrying its proprietary ApoptiCIDe™ cell elimination gene therapy technology targeting…
Read More
June 2, 2022 in 3DBio Therapeutics, Inc., Portfolio, Rapha Capital Management

Doctors Transplant Ear of Human Cells, Made by 3-D Printer

3DBio Therapeutics, a biotech company in Queens, said it had for the first time used 3-D printing to make a…
Read More
June 2, 2022 in 3DBio Therapeutics, Inc., Portfolio, Rapha Capital Management

3DBio Therapeutics and the Microtia-Congenital Ear Deformity Institute Conduct Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial

- AuriNovo™ an investigational, 3D-bioprinted implant was created using a proprietary process leveraging the patient’s own tissue to generate an…
Read More